ATEM Capital Fund

Managing Partner at ATEM Capital with over 15 years in PE/VC and M&A advisory in biotech and pharma. He leads due diligence, deal negotiation, and execution, has served as a board member at Transmedics, and holds a PhD in Stock Markets.

Managing Partner and Head of Scientific Research at ATEM Capital. He previously managed a biotech hedge fund and led scientific due diligence across 50+ investments resulting in seven M&As, and holds a PhD in enzymology and protein engineering.

Managing Partner at ATEM Capital with over a decade of venture capital and private equity experience. She was previously a partner at an investment firm managing a $0.75 billion partnership between Domain Associates and a sovereign high-tech fund, and served on the board of Syndax Pharmaceuticals.

Principal at ATEM Capital with over five years in finance and investment. He has prepared executive summaries and due diligence materials on more than 50 life sciences companies and participated in diligence for three investment deals worth $30M.

Independent consultant on pharmaceutical development and regulatory affairs with over 30 years of experience. He held senior regulatory roles at Wyeth and served 17 years at the FDA, and sits on the boards of AstraZeneca and Cangene.

VP BioPharma Partnership at Guardant Health. He previously served as Chief Business Officer at PatientsLikeMe, CEO of Health Labs Advisory Boards, and SVP at GlaxoSmithKline, and has advised ventures including the Bill & Melinda Gates Foundation.

Physician with 30 years of global biopharmaceutical experience in oncology drug development. He is Head of Medical Affairs at ADC Therapeutics and previously held senior roles at Celgene, Forest Research Institute, and Wyeth Research.

Senior Partner at KRDable consulting focused on drug development and partnerships, and a board member at several organizations. She spent 26 years at Teva in roles spanning business development, regulatory affairs, and global R&D, with focus on CNS, autoimmune, oncology, and women's health.

Full Professor of Medicinal Chemistry at the University of Perugia and inventor of Ocaliva. He is a former President of the European Federation of Medicinal Chemistry and has published over 300 papers and several patents.

Life sciences and biotech R&D expert with over 40 years of experience. He was Senior VP for Science at Alnylam Pharmaceuticals and previously spent ten years at Biogen, with expertise in molecular biology, RNA technologies, and nano-delivery platforms.

Medical Advisor at ATEM Capital and Chief Medical Director at NovaMedica (a Domain Associates subsidiary), with over 15 years in clinical trials, drug development, and investments. He began his career as a neurosurgeon and cardiothoracic surgery resident.